# A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer

> **NCT03301805** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Rgene Corporation** · enrollment: 40 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** BLEX 404

## Key facts

- **NCT ID:** NCT03301805
- **Lead sponsor:** Rgene Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03301805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03301805, "A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03301805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*